F. Dalenc
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Global Cancer Incidence and Screening, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology
Most-Cited Works
- → 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study(2018)38 cited
- → A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.(2011)32 cited
- → 179O Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trial(2024)7 cited
- → Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).(2010)5 cited
- → Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.(2011)4 cited
- → 156TiP Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)(2023)3 cited
- → A Very Favourable Mammographic Screening Impact on Breast Cancer Characteristics and Treatment Modalities in France. Analysis of 2806 Cases.(2009)1 cited
- → Abstract P5-21-01: pT1a, bpN0M0 breast cancer: clinicopathological characteristics and their impact on treatment decision. Central review of the prospective ODISSEE cohort(2012)
- → Phase I study of irinotecan (Iri) and cisplatin (Cp) in combination with pelvic radiotherapy for the treatment (Tt) of advanced cervical cancer (ACC): A GINECO trial(2006)
- → Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French Observational Hermine Study.(2011)